Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

AQL:GR

2.045 EUR 0.009 0.44%

As of 02:15:50 ET on 04/02/2015.

Snapshot for ArQule Inc (AQL)

Open: 2.046 Day's Range: 2.045 - 2.046 Volume: 0
Previous Close: 2.054 52wk Range: 0.797 - 2.319 1-Yr Rtn: +38.27%

Stock Chart for AQL

No chart data available.
  • AQL:GR 2.045
  • 1D
  • 1M
  • 1Y
2.054
Interactive AQL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for AQL

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.3230
Est. PEG Ratio -
Market Cap (M EUR) 128.45
Shares Outstanding (M) 62.81
30 Day Average Volume 2,823
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for AQL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for AQL

ArQule Inc. develops cancer therapeutics based on its proprietary Activated Checkpoint Therapy platform. The Company's platform is designed to produce small molecule compounds that selectively kill cancer cells while leaving normal cells unharmed. ArQule's products are intended to be effective against multiple types of cancer.

Paolo PucciChief Executive OfficerPeter S LawrencePresident/COO/Secy/Gen Cnsl
Brian SchwartzSenior VP/Chief Medical OfcrWilliam B BoniVP:Investor Relations
More Company Profile & Key Executives for AQL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil